logo

FDA Calendar

Share
Company Name AstraZeneca PLC
Drug Name Trastuzumab deruxtecan (BLA)
Event Name FDA decision on Trastuzumab deruxtecan or treatment of patients with HER2-positive metastatic breast cancer
Event Date 04/17/2020
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar

>